Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial
Clinical Trial
[키워드] acute respiratory distress
acute respiratory distress syndrome
adverse effect
ARDS
bone
Bone marrow
cells
cellular
cellular therapy
clinical
Cohort
control patient
control patients
COVID-19
COVID-19 disease
Critical
D-dimer value
Dexamethasone
Efficacy
Endocarditis
evaluate
extracorporeal membrane oxygenation
group
high mortality
High-flow nasal oxygen
Immune cell
Immune-mediated
induce
Inflammation
Inflammatory response
intensive care
intensive care unit (ICU)
interval
intravenous infusion
invasive
Invasive mechanical ventilation
limit
mechanical ventilation
median
Mesenchymal stromal cells
MSC
MSC-treated
MSCs
nasal
no significant difference
observation
outcome
oxygen
Patient
patients
phase
phenotype
Randomized controlled trial
Regulatory
reported
required
requiring supplemental oxygen
Result
Safe
SARS-CoV-2
severe COVID-19
significantly higher
significantly lower
Statistical tests
stimulate
stroke
stromal cell
survival
syndrome
therapy
tissue repair
treated
Trial
[DOI] 10.3389/fimmu.2022.932360 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.3389/fimmu.2022.932360 PMC 바로가기 [Article Type] Clinical Trial